{
  "objCls" : "Guideline",
  "@id" : "https://www.pharmgkb.org/data/guideline/PA166105003",
  "@context" : "https://www.pharmgkb.org/jsonld/guideline.jsonld",
  "id" : "PA166105003",
  "name" : "CPIC Dosing Guideline for allopurinol and HLA-B",
  "groups" : [ {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128786",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128786",
    "name" : "Absent ",
    "annotations" : [ {
      "id" : 1445583358,
      "text" : "Low or reduced risk of allopurinol-induced SCAR",
      "textHtml" : "<p>Low or reduced risk of allopurinol-induced SCAR</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445583357,
      "text" : "Low or reduced risk of allopurinol SCAR (absence of *58:01 alleles (reported as \"negative\" on a genotyping test))",
      "textHtml" : "<p>Low or reduced risk of allopurinol SCAR (absence of *58:01 alleles (reported as \"negative\" on a genotyping test))</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445583359,
      "text" : "Use allopurinol per standard dosing guidelines.",
      "textHtml" : "<p>Use allopurinol per standard dosing guidelines.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:Other/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  }, {
    "objCls" : "DosingGuidelineAnnotationGroup",
    "@id" : "https://www.pharmgkb.org/data/dosingGuidelineAnnotationGroup/PA166128787",
    "@context" : "https://www.pharmgkb.org/jsonld/dosingGuidelineAnnotationGroup.jsonld",
    "id" : "PA166128787",
    "name" : "Present",
    "annotations" : [ {
      "id" : 1445583361,
      "text" : "Significantly increased risk of allopurinol-induced SCAR",
      "textHtml" : "<p>Significantly increased risk of allopurinol-induced SCAR</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501925",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501925,
        "src" : "guidelineTags",
        "term" : "Implications",
        "termId" : "guidelineTags:981501925"
      }
    }, {
      "id" : 1445583360,
      "text" : "Significantly increased risk of allopurinol SCAR (presence of at least one *58:01 allele (reported as \"positive\" on a genotyping test))",
      "textHtml" : "<p>Significantly increased risk of allopurinol SCAR (presence of at least one *58:01 allele (reported as \"positive\" on a genotyping test))</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501927",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501927,
        "src" : "guidelineTags",
        "term" : "Phenotype (Genotype)",
        "termId" : "guidelineTags:981501927"
      }
    }, {
      "id" : 1445583362,
      "text" : "Allopurinol is contraindicated.",
      "textHtml" : "<p>Allopurinol is contraindicated.</p>",
      "type" : {
        "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineTags/guidelineTags:981501928",
        "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
        "id" : 981501928,
        "src" : "guidelineTags",
        "term" : "Recommendations",
        "termId" : "guidelineTags:981501928"
      }
    } ],
    "genotypes" : [ "HLA-B:*58:01/*58:01", "HLA-B:*58:01/Other" ],
    "strength" : {
      "@id" : "https://www.pharmgkb.org/data/ontologyTerm/guidelineStrength/guidelineStrength:981501930",
      "@context" : "https://www.pharmgkb.org/jsonld/ontologyTerm.jsonld",
      "id" : 981501930,
      "src" : "guidelineStrength",
      "term" : "Strong",
      "termId" : "guidelineStrength:981501930"
    }
  } ],
  "relatedChemicals" : [ {
    "objCls" : "Chemical",
    "@id" : "https://www.pharmgkb.org/data/chemical/PA448320",
    "@context" : "https://www.pharmgkb.org/jsonld/chemical.jsonld",
    "id" : "PA448320",
    "name" : "allopurinol"
  } ],
  "relatedGenes" : [ {
    "objCls" : "Gene",
    "@id" : "https://www.pharmgkb.org/data/gene/PA35056",
    "@context" : "https://www.pharmgkb.org/jsonld/gene.jsonld",
    "id" : "PA35056",
    "symbol" : "HLA-B",
    "name" : "major histocompatibility complex, class I, B"
  } ],
  "source" : "CPIC",
  "summaryHtml" : "<p>Allopurinol is contraindicated in individuals with the HLA-B*58:01 variant allele (\"HLA-B*58:01-positive\") due to significantly increased risk of allopurinol-induced SCAR.</p>",
  "textHtml" : "<h3 id=\"June2015\">June 2015</h3><p><em>Accepted article preview online June 2014</em></p><p>The 2015 update of CPIC guidelines regarding allopurinol has been published in <em>Clinical Pharmacology and Therapeutics</em>.  Recent literature was reviewed and there is <strong>no new evidence that would change the original guidelines. Therefore, the dosing recommendations in the original publication remain clinically current</strong>. </p><ul><li>Download and read:<ul><li> <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_allopurinol_update_2015.pdf\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B (HLA-B) Genotype and Allopurinol Dosing: 2015 update</a> </li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_allopurinol_update_supplement_2015.pdf\">2015 supplement</a>. </li></ul></li></ul><h3 id=\"February2013\">February 2013</h3><p><em>Advanced online publication December 2012</em></p><ul><li>Guidelines regarding the use of pharmacogenomic tests in dosing for allopurinol have been published in Clinical Pharmacology and Therapeutics by the Clinical Pharmacogenetics Implementation Consortium <a href=\"/contributors/consortia/cpic_profile.jsp\">(CPIC)</a>.</li><li>These guidelines are applicable to:<ul><li>adults</li></ul></li><li>Excerpt from the 2013 allopurinol dosing guidelines:<ul><li>\"Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout; however, allopurinol is also one of the most common causes of severe cutaneous adverse reactions (SCAR), which includes drug hypersensitivity syndrome, Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). A variant allele of the human leukocyte antigen-B, HLA-B*5801, associates strongly with allopurinol-induced SCAR. We have summarized evidence from the published literatures and develop peer-reviewed guidelines for allopurinol use based on HLA-B genotype.\"</li></ul></li><li>Download and read:<ul><li> <a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Allopurinol.pdf\">Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing</a> </li><li><a href=\"/download.do?objCls=Attachment&amp;objId=CPIC_HLAB-Allopurinol_Supplemental_Material.pdf\">2013 supplement</a>. </li></ul></li></ul><h3 id=\"Table1RecommendeddosingofallopurinolbasedonHLABgenotype\">Table 1: Recommended dosing of allopurinol based on <em>HLA-B</em> genotype</h3><table class=\"table table-striped table-condensed table-hover table-bordered\"><tr><th>Likely Phenotype</th><th>Genotypes</th><th>Examples of diplotypes</th><th>Implications for phenotypic measures</th><th>Recommendations for allopurinol therapy</th><th>Classification of recommendation for allopurinol therapy</th></tr><tr><td>Low or reduced risk of allopurinol SCAR</td><td>Absence of <em>*58:01</em> alleles (reported as \"negative\" on a genotyping test)</td><td>*X/*X <sup>a</sup></td><td>Low or reduced risk of allopurinol SCAR</td><td>Use allopurinol per standard dosing guidelines</td><td>Strong</td></tr><tr><td>Significantly increased risk of allopurinol SCAR</td><td>Presence of at least one <em>*58:01</em> allele (reported as \"positive\" on a genotyping test)</td><td><em>*58:01</em>/*X <sup>a</sup> <em>*58:01/*58:01</em></td><td>Significantly increased risk of allopurinol SCAR</td><td>Allopurinol is contraindicated</td><td>Strong</td></tr></table><p><em>Adapted from Table 2 of the 2013 Guideline Manuscript</em></p><p><sup>a</sup> *X = any <em>HLA-B</em> genotype other than <em>*58:01</em>.<br/><em>HLA-B</em> = human leukocyte antigen B</p>"
}